1. Introduction {#sec1-ijms-19-02367}
===============

Improved understanding of the signaling pathways that regulate cellular functions, including growth and proliferation, has led to the identification of kinases as key drug targets \[[@B1-ijms-19-02367]\]. Dysregulation of receptor and non-receptor tyrosine kinases is a common feature in tumor development and cancer progression \[[@B2-ijms-19-02367]\]. Thus, pharmacological inhibition of tyrosine kinases has been established as a clinically useful approach for the treatment of various types of cancer, and other diseases \[[@B2-ijms-19-02367]\].

Small molecule kinase inhibitors are a rapidly growing class of targeted therapies, with the largest impact in cancer treatment. Imatinib was the first successful small molecule tyrosine kinase inhibitor approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2001 for the treatment of chronic myeloid leukemia \[[@B3-ijms-19-02367]\]. Since that time, over 30 small molecule kinase inhibitors have been approved for clinical use in cancer therapy and other diseases ([Table 1](#ijms-19-02367-t001){ref-type="table"}) \[[@B4-ijms-19-02367]\]. Tyrosine kinase inhibitors represent approximately 75% of all small molecule kinase inhibitors \[[@B4-ijms-19-02367]\]. The therapeutic indications for tyrosine kinase inhibitors include the treatment of several types of cancer, such as leukemia, lung, breast, kidney, gastrointestinal, and skin cancers. A smaller number of kinase inhibitors have non-cancer indications, including rheumatoid arthritis (tofacitinib) and pulmonary fibrosis (nintedanib) \[[@B4-ijms-19-02367]\]. Several other kinase inhibitors are currently in clinical trials.

One of the assumed benefits of molecular targeted anticancer agents is that they generally lack the cytotoxic effects of traditional chemotherapies; however, they introduce new challenges to optimize drug therapy \[[@B5-ijms-19-02367]\]. Unlike traditional chemotherapies, small molecule tyrosine kinase inhibitors are administered orally, and most are administered at fixed doses. Severe toxicities, including hepatotoxicity and cardiotoxicity, limit the use of tyrosine kinase inhibitors in some patients.

Drug-induced liver injury (hepatotoxicity) has been associated with several tyrosine kinase inhibitors in clinical use \[[@B6-ijms-19-02367],[@B7-ijms-19-02367],[@B8-ijms-19-02367],[@B9-ijms-19-02367]\]. Mandatory black-box warnings for severe and fatal idiosyncratic hepatotoxicity have been issued for five tyrosine kinase inhibitors: lapatinib, sunitinib, pazopanib, regorafenib, and ponatinib. The non-tyrosine kinase inhibitor idelalisib also carries a black-box warning for hepatotoxicity. The underlying mechanisms of hepatotoxicity associated with these agents remain largely unknown. This represents a significant challenge in cancer therapy and drug development. Understanding the mechanisms and risk factors of drug-induced liver injury has major implications for improving prediction and prevention of these events \[[@B10-ijms-19-02367]\].

Metabolic activation (bioactivation) of small molecule kinase inhibitors by cytochrome P450 (CYP) enzymes leading to formation of chemically reactive products is proposed as a key initiating event in tyrosine kinase inhibitor-induced hepatotoxicity. Several tyrosine kinase inhibitors have been shown to undergo bioactivation to form reactive metabolites. This topic has been reviewed, with excellent articles by Duckett and Cameron, \[[@B11-ijms-19-02367]\] Stepan et al. \[[@B13-ijms-19-02367]\] and Teo et al. \[[@B14-ijms-19-02367]\] Reactive metabolites have been identified for the following clinically available tyrosine kinase inhibitors: dasitinib \[[@B15-ijms-19-02367]\], gefitinib \[[@B16-ijms-19-02367]\]. erlotinib \[[@B17-ijms-19-02367]\], lapatinib \[[@B18-ijms-19-02367],[@B19-ijms-19-02367]\], imatinib \[[@B20-ijms-19-02367]\], axitinib \[[@B21-ijms-19-02367]\], ponatinib \[[@B22-ijms-19-02367]\], sunitinib \[[@B23-ijms-19-02367]\], as well as investigational tyrosine kinase inhibitors. The purpose of the present review is to (1) provide updates on recently characterized bioactivation mechanisms of selected tyrosine kinase inhibitors, (2) discuss progress towards elucidating the cellular mechanisms of hepatocellular injury related to tyrosine kinase inhibitors, and (3) briefly discuss recent findings related to risk factors of tyrosine kinase inhibitor-induced hepatotoxicity.

2. Bioactivation of Small Molecule Tyrosine Kinase Inhibitors {#sec2-ijms-19-02367}
=============================================================

Screening approaches to detect the formation of reactive electrophilic metabolites have been well established. These approaches often involve the use of trapping agents, such as glutathione (GSH), potassium cyanide (KCN), and methoxylamine in incubations with human liver microsomes or S9 fraction (cytosol + microsomes) fortified with nicotinamide adenine dinucleotide phosphate (NADPH) \[[@B24-ijms-19-02367],[@B25-ijms-19-02367],[@B26-ijms-19-02367],[@B27-ijms-19-02367]\]. It should also be noted that the mechanism of action of four of the current FDA-approved tyrosine kinase inhibitors involves covalent modification and irreversible inhibition of their pharmacologic targets. These drugs and their targets include ibrutinib (BTK), afatinib (EGFR, HER2, HER4), osimertinib (EGFR), and neratinib (EGFR, HER2, HER4).

2.1. Screening for Time-Dependent Inhibition and Reactive Metabolite Formation {#sec2dot1-ijms-19-02367}
------------------------------------------------------------------------------

Metabolism by CYP3A enzymes is the predominate route of drug elimination for most small molecule tyrosine kinase inhibitors \[[@B11-ijms-19-02367],[@B28-ijms-19-02367]\]. CYP3A enzymes have been shown to play a major role in drug bioactivation; CYP1A enzymes are also reported to catalyze the bioactivation of some tyrosine kinase inhibitors. Recent studies indicate that many tyrosine kinase inhibitors cause time-dependent inhibition of cytochrome P450 enzymes, particularly CYP3A, in vitro \[[@B26-ijms-19-02367]\]. Mechanism based-inactivation of CYP3A has been characterized for dasatinib \[[@B15-ijms-19-02367]\], lapatinib \[[@B18-ijms-19-02367],[@B29-ijms-19-02367]\], axitinib \[[@B21-ijms-19-02367]\], lestaurtinib, and saracatinib \[[@B30-ijms-19-02367]\].

The following studies utilized P450 inactivation parameters to assess the potential for drug--drug interactions with various kinase inhibitors. Kenny et al., reported a systematic screen of tyrosine kinase inhibitors to evaluate time-dependent P450 inhibition and assess the formation of reactive metabolites \[[@B26-ijms-19-02367]\]. This analysis included nine tyrosine kinase inhibitors, eight of which were found to cause time-dependent inhibition (TDI) of cytochrome P450 enzymes---most commonly CYP3A \[[@B26-ijms-19-02367]\]. The TDI was determined by the shift in the area under the curve (AUC) of the IC~50~ curve. Testosterone and midazolam were both used as probe substrates for CYP3A. Detailed kinetic parameters (K~I~, k~inact~) were also determined for TDI-positive compounds. Evidence of reactive metabolite formation was found for nine of the tyrosine kinase inhibitors tested (dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, sorafenib, and sunitinib) \[[@B26-ijms-19-02367]\]. Tyrosine kinase inhibitors were listed with the intensity and number of GSH, cyanide, and methoxylamine conjugates formed \[[@B26-ijms-19-02367]\].

In another study, Filppula et al. screened 14 kinase inhibitors for time-dependent inhibition of CYP3A and CYP2C8 \[[@B30-ijms-19-02367]\]. Amodiaquine *N*-deethylation was used as the marker reaction for CYP2C8 activity, and midazolam 1'-hydroxylation was used as the marker for CYP3A activity in human liver microsomes \[[@B30-ijms-19-02367]\]. Time-dependent inhibition was assessed by IC~50~ shift assay with the 14 kinase inhibitors. Detailed mechanism-based inactivation was characterized for bosutinib, lestaurtinib, and saracatinib. Erlotinib and gefitinib were found to activate/stimulate midazolam 1′-hydroxylation in experiments without pre-incubation \[[@B30-ijms-19-02367]\]. Bosutinib was found to cause time-dependent inhibition of CYP2C8-mediated amodiaquine *N*-deethylation ("weak mechanism-based inactivation"), and lestaurtinib and saracatinib were found to cause time-dependent inhibition (mechanism-based inactivation) of CYP3A-mediated midazolam 1′-hydroxylation \[[@B30-ijms-19-02367]\].

Wang et al. also assessed the ability of 12 small molecule kinase inhibitors to inhibit CYP2C8- and CYP3A4-mediated metabolism of paclitaxel, a cytotoxic agent commonly used in combination cancer therapy \[[@B21-ijms-19-02367]\]. In addition to kinase inhibitors previously shown to inactivate CYP3A4, axitinib was also found to inactivate CYP3A4 in a time- and concentration-dependent manner.

2.2. Bioactivation Mechanisms of Specific Tyrosine Kinase Inhibitors {#sec2dot2-ijms-19-02367}
--------------------------------------------------------------------

The bioactivation mechanisms of several tyrosine kinase inhibitors have been well defined. Previous reviews \[[@B11-ijms-19-02367],[@B13-ijms-19-02367],[@B14-ijms-19-02367]\] have focused on the bioactivation pathways of dasitinib \[[@B15-ijms-19-02367]\], gefitinib \[[@B16-ijms-19-02367]\], erlotinib \[[@B17-ijms-19-02367]\], and lapatinib \[[@B18-ijms-19-02367]\] ([Table 2](#ijms-19-02367-t002){ref-type="table"}). Briefly, dasatinib was shown to undergo bioactivation by CYP3A4 to form quinoneimine and imine methide intermediates \[[@B15-ijms-19-02367]\]. CYP3A-mediated bioactivation of gefitinib \[[@B16-ijms-19-02367]\], erlotinib \[[@B17-ijms-19-02367]\], and lapatinib \[[@B18-ijms-19-02367]\] results in the formation of quinoneimine intermediates. Extrahepatic CYP1A1 was also shown to contribute to metabolic activation of gefitinib and erlotinib \[[@B16-ijms-19-02367],[@B17-ijms-19-02367]\]. Reactive metabolites of these drugs were trapped as stable GSH conjugates. More recently, Zhao et al. described a novel bioactivation pathway of erlotinib mediated by CYP3A4 and CYP3A5 to form a reactive ketene intermediate, which was trapped as an adduct with 4-bromobenzylamine \[[@B31-ijms-19-02367]\]. In addition to these tyrosine kinase inhibitors, imatinib \[[@B20-ijms-19-02367]\], axitinib \[[@B21-ijms-19-02367]\], ponatinib \[[@B22-ijms-19-02367]\], and sunitinib \[[@B23-ijms-19-02367]\], have been shown to undergo bioactivation to form reactive metabolites, which were trapped as stable adducts. Recent findings regarding the bioactivation mechanisms of these tyrosine kinase inhibitors will be discussed below.

### 2.2.1. Imatinib {#sec2dot2dot1-ijms-19-02367}

Imatinib, an inhibitor of breakpoint cluster region protein (BCR)-ABL, platelet-derived growth factor receptor (PDGFR), and c-Kit, was the first FDA-approved small molecule tyrosine kinase inhibitor, indicated for the treatment of Philadelphia chromosome-positive (Ph^+^) chronic myeloid leukemia (CML), acute lymphatic leukemia (ALL), and other types of cancer \[[@B3-ijms-19-02367]\]. In the study by Kenny et al., seven cyanide conjugates and one methoxylamine conjugate were observed from liver microsomal incubations in vitro \[[@B26-ijms-19-02367]\]. Li et al., characterized the bioactivation of imatinib at the piperizine ring to form imine and imine--carbonyl (α,β-unsaturated) intermediates, and bioactivation of the *p*-toluidine moiety to form imine--methide intermediates trapped as cyanide adducts \[[@B20-ijms-19-02367]\].

### 2.2.2. Axitinib {#sec2dot2dot2-ijms-19-02367}

Axitinib is an inhibitor of VEGFR approved for the treatment of advanced renal cell carcinoma \[[@B32-ijms-19-02367]\]. As described above, axitinib was found to cause TDI of CYP3A4 \[[@B21-ijms-19-02367]\]. In studies to examine the mechanism of CYP3A4 inactivation by axitinib, two GSH conjugates of axitinib were detected \[[@B21-ijms-19-02367]\]. One GSH conjugate was formed in the absence of NADPH, and the other GSH conjugate was formed in an NADPH-dependent manner, suggesting P450-mediated bioactivation for the later. The bioactivation mechanism of axitinib was proposed to involve epoxidation \[[@B21-ijms-19-02367]\].

### 2.2.3. Ponatinib {#sec2dot2dot3-ijms-19-02367}

Ponatinib is an inhibitor of BCR-ABL tyrosine kinase and is approved for the treatment of resistant CML and Philadelphia chromosome-positive ALL \[[@B35-ijms-19-02367]\]. Lin et al., studied ponatinib bioactivation in vitro, and ponatinib pharmacokinetics in vivo, in wild-type and humanized CYP1A1/2 mice \[[@B22-ijms-19-02367]\]. In incubations of ponatinib with recombinant P450 enzymes supplemented with NADPH and GSH, GSH conjugates of ponatinib were formed primarily by CYP1A1 \[[@B22-ijms-19-02367]\]. Co-incubation with recombinant mouse glutathione *S*-transferase (mGstp 1) enhanced the formation of GSH conjugates. Ponatinib--Gstp1 adducts were also detected from incubations of ponatinib with CYP1A1 and Gstp1 \[[@B22-ijms-19-02367]\]. The proposed ponatinib bioactivation pathway was suggested to involve epoxide formation \[[@B22-ijms-19-02367]\] however, the detailed reaction mechanism has not been characterized.

In vivo, wild-type mice were pretreated with the aryl hydrocarbon receptor (AhR) activator TCDD (2,3,7,8-tetrachlorodibenzodioxin), and humanized CYP1A1/2 mice were pretreated with 3-methylcholanthrene (3-MC) followed by administration of ponatinib. Activation of AhR in wild-type mice resulted in increased clearance of ponatinib leading to 87% reduction in AUC and 62% decrease in half-life compared to untreated wild-type mice \[[@B22-ijms-19-02367]\]. Ponatinib clearance was also increased in humanized CYP1A1/2 mice pretreated with 3-MC (54% reduction in AUC and 67% reduction in half-life) compared to untreated humanized mice. Ponatinib GSH conjugates were detected in fecal samples of 3-MC pretreated humanized CYP1A1/2 mice, but not in the feces of vehicle-treated mice \[[@B22-ijms-19-02367]\]. The results of this study indicate that CYP1A induction may enhance formation of ponatinib reactive metabolites in vivo \[[@B22-ijms-19-02367]\]. Since CYP1A1 is not appreciably expressed in liver, the role of CYP1A1 in ponatinib bioactivation may be important in extra-hepatic tissues, such as lung \[[@B36-ijms-19-02367]\].

### 2.2.4. Sunitinib {#sec2dot2dot4-ijms-19-02367}

Sunitinib is an inhibitor of multiple tyrosine kinases, including VEGFR, PDGFR, and c-Kit, and is approved for the treatment of metastatic renal cell carcinoma, imatinib-resistant gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors \[[@B37-ijms-19-02367],[@B38-ijms-19-02367]\]. As stated above, Kenny et al., reported the formation of reactive metabolites from sunitinib in vitro based on detection of two GSH conjugates; however, the structures of the reactive metabolites were not characterized \[[@B26-ijms-19-02367]\]. Later, Xie et al. demonstrated formation of reactive metabolite--GSH conjugates from sunitinib and its structural analog famitinib in human microsomal incubations \[[@B39-ijms-19-02367]\]. These findings prompted further investigations into the bioactivation pathways of sunitinib. Amaya et al., recently reported identification of the cytochrome P450 enzymes involved in sunitinib metabolic activation \[[@B23-ijms-19-02367]\]. A putative quinoneimine reactive metabolite trapped as a GSH conjugate was detected from human liver microsomal incubations supplemented with NADPH and GSH. CYP1A2 and CYP3A4 were shown to be the primary hepatic enzymes involved in sunitinib bioactivation, and CYP1A1, an extrahepatic P450, also generated reactive metabolite--GSH conjugates. The bioactivation mechanism was proposed to involve oxidative defluorination and quinoneimine formation, which has been previously described for famitinib and gefitinib \[[@B16-ijms-19-02367],[@B39-ijms-19-02367]\]. Notably, formation of GSH conjugates of the putative sunitinib quinoneimine was higher in human liver microsomes with high CYP1A2 activity compared to human liver microsomes with low CYP1A2 activity \[[@B23-ijms-19-02367]\]. Since smoking is known to induce CYP1A enzymes, it is possible that smoking may increase the generation of sunitinib reactive metabolites. The effect of smoking on sunitinib metabolism in vivo warrants further investigation.

The parent drug sunitinib contains a chemically reactive α,β-unsaturated carbonyl moiety, which can undergo Michael addition with cellular thiols, such as GSH and cysteine residues of proteins. Thus, GSH conjugates can form directly from the parent drug. GSH conjugates of sunitinib parent drug were detected in incubations without NADPH, which demonstrates the intrinsic reactivity of the drug \[[@B23-ijms-19-02367]\]. Additional studies are required to determine whether the parent drug sunitinib and/or its reactive quinoneimine metabolite exert organ toxicities due to covalent binding of cellular proteins, oxidative stress, or other mechanism(s).

2.3. Bioactivation of Investigational Tyrosine Kinase Inhibitors {#sec2dot3-ijms-19-02367}
----------------------------------------------------------------

### 2.3.1. Saracatinib {#sec2dot3dot1-ijms-19-02367}

Saracatinib (AZD-0530) is an inhibitor of the Src kinase family and BCR-ABL tyrosine kinase, and this compound is in clinical trials for anticancer therapy \[[@B40-ijms-19-02367]\]. Saracatinib contains a 1,3-benzodioxole moiety and an *N*-methyl piperazine group. Chen et al., demonstrated that saracatinib undergoes bioactivation predominately by CYP3A4 \[[@B33-ijms-19-02367]\]. The proposed bioactivation mechanism involved demethylenation of the 1,3-benzodioxole moiety to form a catechol and further oxidation to generate an electrophilic ortho-quinone, which was trapped as a GSH conjugate \[[@B33-ijms-19-02367]\]. The saracatinib GSH conjugate was observed in vitro in human and rat microsomal incubations, and in vivo in the bile of rats treated with saracatinib \[[@B33-ijms-19-02367]\]. This bioactivation pathway is suggested to contribute to inactivation of CYP3A and saracatinib-induced toxicities, including pulmonary and hepatic toxicity \[[@B33-ijms-19-02367]\].

Saracatinib was further characterized as a mechanism-based inactivator of CYP3A \[[@B30-ijms-19-02367]\]. In time-dependent inhibition IC~50~ shift assays with saracatinib, the IC~50~ for CYP3A shifted from IC~50~ = 46.0 μM with no preincubation to 1.8 μM with a 30 min preincubation, representing a 26-fold reduction in IC~50~ \[[@B30-ijms-19-02367]\]. The inhibition occurred in a time-, inhibitor concentration-, and NADPH-dependent manner. The inactivation parameters of CYP3A by saracatinib were *K~I~* = 12.6 μM, and *k*~inact~ = 0.096 min^−1^ \[[@B30-ijms-19-02367]\]. Thus, CYP3A inactivation by saracatinib could occur at therapeutic concentrations. Saracatinib was predicted to cause a ≥2.7-fold increase in the AUC of CYP3A substrates \[[@B30-ijms-19-02367]\]. In addition to GSH conjugates, Attwa et al., recently reported detection of three cyano adducts derived from iminium intermediates from bioactivation of the piperizine ring of saracatinib in rat human liver microsomes \[[@B41-ijms-19-02367]\].

### 2.3.2. Masitinib {#sec2dot3dot2-ijms-19-02367}

Masitinib is a tyrosine kinase inhibitor that has anti-inflammatory and antitumor activity. In vitro, masitinib has an inhibitory effect on c-Kit wild type and mutate forms (exon 9 and 11) \[[@B42-ijms-19-02367]\]. Masitinib is currently in clinical trials for the treatment for Alzheimer's disease, gastrointestinal stromal tumors, and amyotrophic lateral sclerosis. Masitinib is structurally similar to imatinib, a tyrosine kinase inhibitor for which multiple cases of liver injury have been reported \[[@B27-ijms-19-02367]\]. A European Medicines Agency assessment report for masitinib reported that the major metabolite of masitinib in mice, rats, dogs, and humans is the product of masitinib demethylation \[[@B43-ijms-19-02367]\]. A genotoxic metabolite of masitinib was also reported. In a study by Amer et al., multiple metabolites of masitinib were identified from incubations with rat liver microsomes \[[@B34-ijms-19-02367]\]. Eight cyano adducts were detected from microsomal incubations with potassium cyanide. The bioactivation reactions were proposed to occur on the piperazine moiety of masitinib to generate imine and imine--carbonyl intermediates, similar to the bioactivation of imatinib \[[@B34-ijms-19-02367]\].

3. Downstream Toxicity Mechanisms of Tyrosine Kinase Inhibitors {#sec3-ijms-19-02367}
===============================================================

Several mechanisms have been proposed to contribute to drug-induced liver injury, and it is likely that multiple concerted pathways are involved \[[@B44-ijms-19-02367],[@B45-ijms-19-02367],[@B46-ijms-19-02367]\]. Formation of reactive metabolites is hypothesized to be a key initiating event in tyrosine kinase inhibitor-induced hepatotoxicity. Reactive electrophilic metabolites can covalently modify cellular proteins and/or induce reactive oxygen species production (oxidative stress), potentially leading to direct cell stress, mitochondrial dysfunction, and/or activation of immune-mediated reactions \[[@B10-ijms-19-02367],[@B47-ijms-19-02367]\]. Alternatively, disruption of bile acid homeostasis due to inhibition of hepatobiliary transporters by drugs or drug metabolites has been shown to play a role in cholestatic liver injury \[[@B45-ijms-19-02367],[@B48-ijms-19-02367],[@B49-ijms-19-02367]\].

Few studies have examined the downstream cellular effects of tyrosine kinase inhibitors and their metabolites as it relates to the pathogenesis of drug-induced liver injury. The mechanisms remain largely unknown; however, recent studies have begun to provide insight into the cellular pathways of tyrosine kinase inhibitor-induced hepatotoxicity. Much of the work in these studies has focused on the effects of tyrosine kinase inhibitors on mitochondrial function and cell signaling pathways leading to toxicity.

Finding the appropriate cell model for detailed mechanistic studies on drug-induced liver injury is a challenge. A key step in elucidating the underlying mechanisms of drug-induced hepatotoxicity is to determine whether the toxicity arises from the parent drug or its metabolite(s). Use of a metabolically competent hepatic cell model is preferred; however, the availability of primary hepatocytes, reproducibility, and technical ease of use can be limitations. The metabolically competent human HepaRG cell line is a useful tool because, among other features, CYP expression is inducible using prototypical inducers \[[@B50-ijms-19-02367],[@B51-ijms-19-02367],[@B52-ijms-19-02367],[@B53-ijms-19-02367],[@B54-ijms-19-02367]\]. Many mechanistic toxicologic studies are performed using the hepatoma cell line HepG2 cells. A key limitation to this model is that HepG2 cells do not have significant cytochrome P450 drug metabolism activity. Various approaches can be employed to optimize this common in vitro system, such as the use of HepG2 cells transfected with CYP enzymes. Biochemical manipulations in HepG2 may also be useful in addressing specific mechanistic questions. For example, depriving cells of glucose and supplementing growth media with galactose requires cells to utilize the mitochondrial respiratory chain to generate ATP instead of relying on glycolysis for ATP, and this sensitizes cells to mitochondrial toxicants \[[@B55-ijms-19-02367]\]. Culturing cells under glucose conditions favors glycolysis, and culturing cells under galactose conditions favors mitochondrial metabolism. Thus, comparing the viability of cells grown in glucose vs galactose is used experimentally to detect drugs that cause mitochondrial dysfunction \[[@B55-ijms-19-02367]\].

The nuclear factor erythroid 2-related factor (Nrf2) pathway is activated in response to oxidative and electrophilic stress, leading to transcription of cytoprotective genes, such as NAD(P)H: quinone oxidoreductase 1 (NQO-1) and heme-oxygenase 1 (HO-1). Cellular electrophilic stress is sensed by Keap 1 in the cytosol \[[@B56-ijms-19-02367],[@B57-ijms-19-02367]\]. In the presence of oxidative and electrophilic stress, Nrf2 translocates from the cytosol to the nucleus, where it binds with its heterodimer partner musculo-aponeurotic factor protein (Maf) to the antioxidant response element (ARE) to activate gene transcription. Thus, activation of the antioxidant response via the Nrf2 pathway may also be monitored as an indicator of drug-induced cell stress. The use of these and other approaches to study tyrosine kinase inhibitor-associated hepatotoxicity is discussed below.

3.1. Dasatinib {#sec3dot1-ijms-19-02367}
--------------

Dasatinib, an inhibitor of BCR-ABL and SRC kinases, is a second-generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Xue et al., examined dasatinib-induced hepatic injury in rat primary hepatocytes and in vivo in rats treated with dasatinib \[[@B58-ijms-19-02367]\]. Dasatinib induced hepatic injury in vitro in a time- and dose-dependent manner in rat primary hepatocytes \[[@B58-ijms-19-02367]\]. Treatment of rats with dasatinib (25 mg/kg/day) for 10 days increased liver injury markers, including elevated serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH). Detailed mechanistic studies in vitro demonstrated that dasatinib induced apoptosis of rat primary hepatocytes, which was marked by chromatin condensation, caspase-3 cleavage, and poly(ADP-ribose) polymerase (PARP) cleavage. Dasatinib was shown to increase intracellular reactive oxygen species (ROS), as measured by cellular oxidation of the fluorescent probe H~2~DCFDA (2′,7′-dichlorodihydrofluorescein diacetate), decrease GSH levels, and decrease superoxide dismutase (SOD) activity in a dose-dependent manner \[[@B58-ijms-19-02367]\]. Dasatinib was also shown to activate Nrf2 and induce phosphorylation of p38 kinase, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK) \[[@B58-ijms-19-02367]\]. Hepatic oxidative stress caused by dasatinib is proposed to involve the CYP3A4-mediated generation of electrophilic metabolites of dasatinib, including a quinoneimine, which can react with GSH and cysteine residues of proteins \[[@B15-ijms-19-02367]\]. Pretreatment of rat hepatocytes with *N*-acetylcysteine attenuated the toxic effects of dasatinib \[[@B58-ijms-19-02367]\].

3.2. Lapatinib {#sec3dot2-ijms-19-02367}
--------------

Lapatinib is a dual inhibitor of EGFR and HER2 tyrosine kinases, and lapatinib is approved in combination therapy for the treatment of advanced and metastatic breast cancer \[[@B59-ijms-19-02367]\]. Lapatinib-induced hepatotoxicity is proposed to involve CYP3A-mediated *O*-dealkylation of lapatinib and further oxidation to form a reactive quinoneimine metabolite \[[@B18-ijms-19-02367],[@B60-ijms-19-02367]\]. Hardy et al., reported studies on the role of metabolic activation on the cytotoxicity of lapatinib in HepaRG cells, a metabolically competent human hepatic cell line \[[@B61-ijms-19-02367]\]. In this investigation, the *O*-dealkylated metabolite of lapatinib was significantly more cytotoxic (LD~50~ = 38.5 ± 1.1 µM) than lapatinib (LD~50~ = 84.9 ± 1.1 µM) itself (*p* \< 0.01) \[[@B61-ijms-19-02367]\]. GSH conjugation of electrophilic metabolites is an important detoxification pathway in vivo. GSH conjugates can undergo further metabolism in hepatic cell cultures and in vivo via the mercapturic acid pathway to form cysteine and *N*-acetylcysteine conjugates. Cysteine conjugates of the putative lapatinib quinoneimine were detected in HepaRG cells incubated with lapatinib. Induction of CYP3A4 by prototypical inducers, rifampin and dexamethasone, increased formation of *O*-dealkylated lapatinib and reactive metabolite cysteine conjugates \[[@B61-ijms-19-02367]\]. CYP3A4 induction also potentiated the cytotoxicity of lapatinib \[[@B61-ijms-19-02367]\]. Further, depletion of GSH using [l]{.smallcaps}-buthionine sulfoximine (BSO) enhanced the cytotoxicity of lapatinib. These findings suggest that CYP3A-mediated metabolic activation plays a key role in lapatinib-induced hepatocellular injury \[[@B61-ijms-19-02367]\].

Eno et al. examined the cellular effects of lapatinib vs its *O*-dealkylated metabolite in HepG2 cells \[[@B62-ijms-19-02367]\]. Mitochondrial respiration, as measured by oxygen consumption rate, was monitored using a Seahorse XF24 analyzer. The results of this study demonstrated that *O*-dealkylated lapatinib caused mitochondrial dysfunction in a time- and concentration-dependent manner. Treatment of HepG2 cells with 30 μM *O*-dealkylated lapatinib for 24 h significantly reduced basal and maximal oxygen consumption rate compared to untreated cells \[[@B62-ijms-19-02367]\]. The parent drug lapatinib did not significantly alter mitochondrial respiration in HepG2 cells at the concentration tested (10 μM lapatinib). This observation is consistent with the fact that HepG2 cells lack the cytochrome P450 drug metabolism activity required to convert lapatinib to the potentially toxic metabolite. However, in HepG2 cells transfected with CYP3A4, 10 μM lapatinib significantly reduced the mitochondrial respiration \[[@B62-ijms-19-02367]\]. This finding suggests that mitochondrial dysfunction is mediated by metabolism of lapatinib to the *O*-dealkylated metabolite. Pretreatment of HepG2 cells with BSO to deplete intracellular GSH followed by incubation with 20 μM *O*-dealkylated lapatinib resulted in a marked reduction in oxygen consumption rate compared to cells treated with *O*-dealkylated lapatinib alone. This indicates that GSH depletion enhanced *O*-dealkylated lapatinib-induced mitochondrial dysfunction \[[@B62-ijms-19-02367]\].

Eno et al. further examined the effect of *O*-dealkylated lapatinib on oxidant stress responses in HepG2 cells \[[@B62-ijms-19-02367]\]. Treatment of HepG2 cells with 40 µM *O*-dealkylated lapatinib increased mRNA expression of mitochondrial SOD2 but did not alter cytoplasmic SOD1 mRNA expression. Nrf2 activation was measured using an ARE-reporter assay \[[@B62-ijms-19-02367]\]. *O*-dealkylated lapatinib was shown to activate Nrf2 in a concentration-dependent manner, and treatment of HepG2 cells with 40 µM *O*-dealkylated lapatinib for 4 h induced expression of Nrf2 target genes, NQO-1 and HO-1. Lapatinib-induced liver injury was also evaluated in vivo in wild-type and Nrf2-knockout mice \[[@B62-ijms-19-02367]\]. Treatment of wild-type and Nrf2-knockout mice with lapatinib (400 mg/kg per day for 5 days) resulted in an increase in ALT and AST. The elevated ALT and AST levels returned back to normal in wild-type mice at day 5 of lapatinib treatment; however, ALT and AST levels remained high in Nrf2-knockout mice, suggesting that the Nrf2 pathway was important in protecting mice from hepatic injury \[[@B62-ijms-19-02367]\].

3.3. Regorafenib {#sec3dot3-ijms-19-02367}
----------------

Regorafenib is a multi-targeted tyrosine kinase inhibitor approved for the treatment of metastatic colorectal cancer and imatinib- and sunitinib-resistant gastrointestinal stromal tumors \[[@B63-ijms-19-02367]\]. The product label for regorafenib carries a black-box warning for hepatotoxicity. Liver injury associated with regorafenib is considered idiosyncratic, and is characterized primarily as hepatocellular injury. Weng et al., examined the mechanisms of regorafenib hepatotoxicity in isolated rat mitochondria and in primary hepatocytes \[[@B64-ijms-19-02367]\]. Regorafenib was shown to cause uncoupling of oxidative phosphorylation, disruption of mitochondrial membrane potential, ATP depletion, and hepatocyte necrosis at clinically relevant concentrations (2.5--15 µM) of regorafenib \[[@B64-ijms-19-02367]\].

3.4. Screening Tyrosine Kinase Inhibitors for Mitochondrial Toxicity {#sec3dot4-ijms-19-02367}
--------------------------------------------------------------------

Studies by Krahenbuhl and colleagues have focused on defining the mitochondrial mechanisms of hepatocellular toxicity induced by tyrosine kinase inhibitors in hepatic cell lines, including HepG2 and HepaRG cells \[[@B65-ijms-19-02367],[@B66-ijms-19-02367]\]. Paech et al., examined the toxic effects of four tyrosine kinase inhibitors (imatinib, sunitinib, lapatinib, and erlotinib) in HepG2 cells, HepaRG cells, and isolated mouse liver mitochondria \[[@B65-ijms-19-02367]\]. In HepG2 cells, cytotoxicity, as characterized by the release of adenylate kinase, was shown for sunitinib at 5--10 µM, and for lapatinib at 10--20 µM, after 24--48 h of incubation. Imatinib and sunitinib (starting at 5 µM) decreased ATP content after 24--48 h of incubation. In HepaRG cells, induction of CYP3A4 by rifampicin (20 µM) enhanced the cytotoxicity of imatinib, lapatinib, and sunitinib, suggesting the role of toxic metabolites in mediating hepatocellular toxicity. This finding is consistent with previous reports by Hardy et al., and Teo et al., which showed that CYP3A induction potentiates the toxicity of lapatinib in hepatic cell cultures \[[@B61-ijms-19-02367],[@B67-ijms-19-02367]\].

Imatinib and sunitinib demonstrated hepatotoxicity by increasing the production of reactive oxygen species, disrupting the mitochondrial membrane potential, depleting GSH content, and inducing apoptosis \[[@B65-ijms-19-02367]\]. Lapatinib also decreased the mitochondrial membrane potential in mouse liver mitochondria and increased production of reactive oxygen species. As noted above, a limitation to this study was that most of the experiments were performed using HepG2 cells, which lack cytochrome P450 drug metabolism activity. However, the findings provide mechanistic insight into effects of the parent drugs on mitochondrial dysfunction. Among the tyrosine kinase inhibitors tested in this study, sunitinib displayed the most potent effects on cellular toxicity \[[@B65-ijms-19-02367]\]. Sunitinib (20 µM) impaired glycolysis and beta oxidation in HepG2 cells, and sunitinib disrupted mitochondrial membrane potential starting at 1 µM in HepG2 cells and 10 µM in isolated mice mitochondria \[[@B65-ijms-19-02367]\]. Sunitinib also diminished the respiration rate in HepG2 cells as concentrations increased by impairing complex I, which stimulated superoxide production. The accumulation of reactive oxygen species started at concentrations as low as 2 µM sunitinib and displayed a sharp increase at 20 µM sunitinib, which corresponded with a dramatic decrease in GSH content \[[@B65-ijms-19-02367]\]. Consequently, the expression of superoxide dismutase 1 in the cytoplasm increased, which was likely due to an antioxidant defense response. The induction of apoptosis indicated by caspase 3/7 activity increased at 20 µM sunitinib, while PARP degradation occurred at 10 µM sunitinib. Although plasma concentrations of sunitinib are 0.1--0.3 µM, concentrations in the liver might be 10-fold higher \[[@B68-ijms-19-02367]\]. This suggests that dose and concentration may play a role in the hepatotoxicity of sunitinib.

Mingard et al., examined the toxic effects of six tyrosine kinase inhibitors (crizotinib, dasatinib, pazotinib, ponatinib, regorafenib, and sorafenib) in HepG2 cells \[[@B66-ijms-19-02367]\]. Regorafenib and sorafenib were shown to cause direct mitochondrial toxicity, as evidenced by increased ATP depletion in HepG2 cells in the presence of galactose compared to glucose \[[@B66-ijms-19-02367]\]. Regorafenib and sorafenib (10 µM) decreased mitochondrial membrane potential in HepG2 cells \[[@B66-ijms-19-02367]\]. Studies were also conducted in HepaRG cells to evaluate the impact of CYP-mediated metabolism of tyrosine kinase inhibitors on mitochondrial toxicity. Unlike studies with lapatinib, sunitinib, and imatinib in HepaRG cells, pretreatment of HepaRG cells with the CYP3A4 inducer rifampicin (20 µM) did not enhance the toxic effects of crizotinib, dasatinib, pazotinib, ponatinib, regorafenib, and sorafenib on mitochondrial membrane integrity or ATP depletion. Rather, intracellular ATP content modestly increased with rifampicin in cells treated with crizotinib (20 µM), dasatinib (50 µM), regorafenib (5 µM), and sorafenib (5 µM) \[[@B66-ijms-19-02367]\]. Ponatinib, regorafenib, and sorafenib were shown to inhibit the mitochondrial electron transport chain. Crizotinib and ponatinib (20 µM) increased superoxide accumulation, and dasatinib and ponatinb (20 µM) caused intracellular GSH depletion. Based on their findings, Mingard et al. suggested a mitochondrial mechanism of hepatotoxicity for regorafenib, sorafenib, and potentially ponatinib, and a non-mitochondrial mechanism of hepatotoxicity for crizotinib, dasatinib, and pazopanib \[[@B66-ijms-19-02367]\].

Zhang et al., screened 31 FDA-approved kinase inhibitors for mitochondrial toxicity using isolated rat mitochondria as a model \[[@B69-ijms-19-02367]\]. Among the kinase inhibitors screened, sorafenib, regorafenib, and pazopanib were found to cause mitochondrial toxicity at therapeutic plasma concentrations (*C*~max~). The finding that sorafenib and regorafenib caused mitochondrial toxicity is consistent with reports by Mingard et al. \[[@B66-ijms-19-02367]\]. Additional kinase inhibitors showed mitochondrial toxicity at higher concentrations (100-fold *C*~max~). As noted above, for some drugs, drug concentrations may be \>10-fold higher in liver compared to plasma; thus, it is relevant to consider drug concentrations in the target tissue in addition to plasma concentrations.

4. Risk Factors of Hepatotoxicity {#sec4-ijms-19-02367}
=================================

An important question to address is: What makes one patient more susceptible to idiosyncratic hepatotoxicity from tyrosine kinase inhibitors compared another patient who does not experience this serious adverse reaction? This is an area of intense ongoing investigation. A better understanding of the genetic and environmental factors that influence tyrosine kinase inhibitor toxicity risk is needed to predict and prevent these adverse events. A number of studies have focused on identifying genetic and environmental risk factors of hepatotoxicity related to tyrosine kinase inhibitors and other classes of drugs. A combination of drug properties and host-specific factors have been proposed to contribute to the development of drug-induced liver injury \[[@B70-ijms-19-02367]\]. Daily dose and body burden of reactive metabolites are identified as important drug-specific factors \[[@B24-ijms-19-02367]\]. Despite knowledge of chemical structural alerts that can undergo bioactivation and the practice of screening for reactive metabolite formation in early stages of drug discovery, hepatotoxicity remains a challenge for recently developed tyrosine kinase inhibitors \[[@B13-ijms-19-02367],[@B71-ijms-19-02367],[@B72-ijms-19-02367],[@B73-ijms-19-02367],[@B74-ijms-19-02367]\]. The proposed host risk factors include human leukocyte antigen (HLA) risk alleles, co-administered drugs, cellular antioxidant capacity, disease state, nutritional status, age, sex, and genetic variations in drug metabolizing enzymes and transporters \[[@B70-ijms-19-02367]\].

The HLA risk allele *HLA-DRB1\*07:01* (and *HLA-DQA1\*02:01*) is associated with severe lapatinib-induced hepatotoxicity \[[@B75-ijms-19-02367],[@B76-ijms-19-02367],[@B77-ijms-19-02367],[@B78-ijms-19-02367],[@B79-ijms-19-02367]\]. This suggests that lapatinib-related liver injury involves activation of the adaptive immune system, which may be triggered by the chemically reactive quinoneimine metabolite of lapatinib. *HLA-B*:\*57-01 was shown to be a risk factor for pazopanib-induced hepatotoxicity, suggesting that an immune-mediated mechanism may be involved \[[@B80-ijms-19-02367]\].

In addition to HLA alleles, co-administered drugs may also impact the risk of hepatotoxicity related to lapatinib. Teo et al., demonstrated that the CYP3A4 inducer dexamethasone increased the risk of lapatinib-induced hepatotoxicity in breast cancer patients \[[@B67-ijms-19-02367]\]. While the highly polymorphic CYP3A5 has been shown to contribute to bioactivation on lapatinib \[[@B29-ijms-19-02367],[@B81-ijms-19-02367],[@B82-ijms-19-02367]\], to our knowledge, no studies have definitively shown a correlation between *CYP3A5* genotype and lapatinib-induced hepatotoxicity.

Identifying the sources of variability in drug exposure for small molecule kinase inhibitors remains a challenge. This is relevant because variations in drug exposure can impact drug efficacy and toxicity. One study reported that *CYP3A5* and *CYP2D6* genotype and phenotype (poor metabolizer vs non-poor metabolizer) may affect the risk of severe hepatotoxicity induced by gefitinib in Japanese patients with non-small cell lung cancer \[[@B83-ijms-19-02367]\]. Teo et al. reported that the relative risk for AST elevations due to sunitinib in an Asian patient population was 2.5 times lower in patients who express *CYP3A5* (individuals homozygous or heterozygous for *CYP3A5\*1*) compared to *CYP3A5* non-expressers (*CYP3A5\*3/\*3*) \[[@B84-ijms-19-02367]\]. Moreover, the relative risk for increases in ALT, AST, and total bilirubin was 2--3 times higher in patients with the ATP binding cassette (ABC) transporter genotype *ABCB1 CC* compared to *ABCB1 CT/TT* \[[@B84-ijms-19-02367]\]. Whether polymorphisms in drug metabolism and transport genes affect patient exposure to reactive metabolites of tyrosine kinase inhibitors in vivo is unknown, and warrants further investigation.

5. Summary {#sec5-ijms-19-02367}
==========

Several tyrosine kinase inhibitors have been shown to undergo cytochrome P450-mediated bioactivation to form chemically reactive metabolites. However, several questions remain to establish the mechanistic link between reactive metabolites and drug toxicity: Does the tyrosine kinase inhibitor cause direct cellular toxicity and/or immune-mediated toxicity? What are the cellular targets and downstream mechanisms involved? Recent findings in the literature suggest that different tyrosine kinase inhibitors have different mechanisms of hepatotoxicity. Thus, a drug- and pathway-specific approach is necessary to better understand the mechanisms of hepatotoxicity associated with individual tyrosine kinase inhibitors. Future studies are needed to elucidate the downstream biochemical, cellular signaling, and immunologic events that lead to tyrosine kinase inhibitor-induced hepatocellular injury. In addition, ongoing research is needed to identify patient-specific risk factors for tyrosine kinase inhibitor-induced liver injury.

6. Methods {#sec6-ijms-19-02367}
==========

Articles were selected using a search on the PubMed database (<https://www.ncbi.nlm.nih.gov/pubmed/>). The search comprised the following keywords: tyrosine kinase inhibitor, reactive intermediate, reactive metabolite, bioactivation. The search was performed on 21 April 2018. In the initial search, a total of 28 results were generated in PubMed for the specific search of "tyrosine kinase inhibitor and reactive metabolite"; 15 results were generated from the search of "tyrosine kinase inhibitor and reactive intermediate"; and 14 results were generated from the search of "tyrosine kinase inhibitor and bioactivation". Several overlapping articles were identified from the individual searches. The article titles were reviewed for relevance to the topic, and for the search of "tyrosine kinase inhibitor and reactive metabolite", 21 articles were excluded because they were not related to cytochrome P450-mediated bioactivation. Additional review articles relevant to the topic were included, and articles cross-referenced in the initial articles were included in the final selection.
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ALK

anaplastic lymphoma kinase

ALL

acute lymphatic leukemia

ALT

alanine aminotransferase

AO

aldehyde oxidase

AST

aspartate aminotransferase

AUC

area under the curve

BID

twice daily

BSO

buthionine sulfoximine

BTK

Bruton's tyrosine kinase

CEL

chronic eosinophilic leukemia

CIM

chronic idiopathic myelofibrosis

CLL

chronic lymphocytic leukemia

CML

chronic myeloid leukemia

CRC

colorectal cancer

CYP

cytochrome P450

EGFR

epidermal growth factor receptor

FGFR

fibroblast growth factor receptor

GIST

gastrointestinal stromal tumors

HCC

hepatocellular carcinoma

HER2

human epidermal growth factor receptor 2

HR

hormone receptor

JAK

Janus kinase

MEK

mitogen-activated extracellular signal-regulated kinase

MTC

metastatic thyroid cancer

Nrf2

nuclear factor erythroid 2-related factor

NSCLC

non-small cell lung cancer

PDGFR

platelet-derived growth factor receptor

pNET

pancreatic neuroendocrine tumors

RCC

renal cell carcinoma

VEGFR

vascular endothelial growth factor receptor
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###### 

Summary of Kinase Inhibitors Approved for Clinical Use.

  Drug                FDA Approval Year *^c^*   Target(s)                                                                  Indication                              Primary Metabolic Pathway \[[@B11-ijms-19-02367],[@B12-ijms-19-02367]\]
  ------------------- ------------------------- -------------------------------------------------------------------------- --------------------------------------- -------------------------------------------------------------------------
  Imatinib            2001                      Bcr-Abl, PDGFR, c-KIT                                                      Ph^+^ CML, ALL, GIST, CEL               CYP3A4, CYP3A5
  Gefitinib           2003                      EGFR                                                                       NSCLC                                   CYP3A4, CYP3A5, CYP2D6, (CYP1A1 minor)
  Erlotinib           2004                      EGFR                                                                       NSCLC                                   CYP3A4, CYP1A2, CYP1A1
  Sorafenib           2005                      C-RAF, B-RAF, c-KIT, FLT3, VEGFR, PDGFR                                    HCC, RCC                                CYP3A4, UGT1A9
  Sunitinib *^a^*     2006                      PDGFR, VEGFR, c-KIT, RET, CSF-1R, FLT3                                     RCC, GIST, pNET                         CYP3A4 (major), CYP3A5, CYP1A1, CYP1A2
  Dasatinib           2006                      Bcr-Abl, SCR-family kinases, PDGFR, c-KIT, ephrin (EPH) receptor kinases   CML, ALL                                CYP3A4 (major), FMO-3, UGT
  Lapatinib *^a^*     2007                      EGFR, HER-2                                                                HER2+ breast cancer                     CYP3A4, CYP3A5
  Nilotinib           2007                      Bcr-Abl                                                                    CML                                     CYP3A4, CYP2C8
  Pazopanib *^a^*     2009                      VEGFR, PDGFR, c-KIT                                                        RCC                                     CYP3A4, (CYP1A2, CYP2C8 minor)
  Vandetinib          2011                      EGFR, VEGFR                                                                MTC                                     CYP3A4, FMO-1 & -3
  Crizotinib          2011                      ALK                                                                        NSCLC                                   CYP3A4, CYP3A5
  Vemurafenib         2011                      BRAF                                                                       melanoma                                CYP3A4
  Ruxolitinib         2011                      JAK                                                                        CIM, polycythemia vera, myelofibrosis   CYP3A4, CYP2C9
  Ponatinib *^a^*     2012                      ABL, KIT, RET                                                              CML, ALL                                CYP3A4, (CYP2C8, 2D6, 3A5 minor)
  Regorafenib *^a^*   2012                      RET, VEGFR, PDGFR, other                                                   CRC, GIST                               CYP3A4, UGT1A9
  Axitinib            2012                      VEGFR                                                                      RCC                                     CYP3A4, CYP3A5
  Bosutinib           2012                      Bcr-Abl                                                                    CML                                     CYP3A4
  Cabozantinib        2012                      MET, VEGFR                                                                 MTC                                     CYP3A4
  Tofacitinib         2012                      JAK                                                                        rheumatoid arthritis                    CYP3A4, (CYP2C19 minor)
  Ibrutinib           2013                      BTK                                                                        mantle cell lymphoma, CLL               CYP3A, (CYP2D6 minor)
  Afatinib *^b^*      2013                      EGFR, HER2, HER4                                                           NSCLC                                   negligible
  Trametinib          2013                      MEK                                                                        melanoma                                carboxylesterases
  Dabrafenib          2013                      BRAF                                                                       melanoma                                CYP2C8, CYP3A4
  Ceritinib           2014                      ALK                                                                        NSCLC                                   CYP3A
  Nintedanib          2014                      FGFR, PDGFR, VEGFR                                                         pulmonary fibrosis                      UGT1A1,7,8, (CYP3A4 minor)
  Idelalisib *^a^*    2014                      PI3K, B-cell R                                                             CLL                                     CYP3A, AO, UGT1A4
  Osimertinib *^b^*   2015                      EGFR                                                                       NSCLC                                   CYP3A
  Alectinib           2015                      ALK                                                                        NSCLC                                   CYP3A4
  Cobimetinib         2015                      BRAF                                                                       advanced melanoma                       CYP3A, UGT2B7
  Lenvatinib          2015                      VEGFR, PDGFR                                                               thyroid cancer, RCC                     CYP3A, AO
  Palbociclib         2015                      Cyclin-dependent kinase                                                    HER2-, HR+ breast cancer                CYP3A, SULT2A1
  Brigatinib          2017                      ALK                                                                        NSCLC                                   CYP2C8, CYP3A4
  Neratinib *^b^*     2017                      EGFR, HER2, HER4                                                           HER2+ breast cancer                     CYP3A4, FMO
  Ribociclib          2017                      Cyclin-dependent kinase                                                    EGFR-, HR+ breast cancer                CYP3A4

*^a^* Kinase inhibitors whose product labels have a black-box warning for hepatotoxicity; *^b^* Kinase inhibitors in which covalent modification is involved in the pharmacologic mechanism of action; *^c^* Drug prescribing information was used to confirm FDA approval year, target(s), indication, and metabolic pathway(s).
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###### 

Tyrosine Kinase Inhibitors Reported to Form Reactive Metabolites.

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Drug                    Daily Dose *^a^*   Bioactivation Pathway   Reactive Intermediate(s)   Reference
  ----------------------- ------------------ ----------------------- -------------------------- -------------------------------------------------
  Dasatinib               100--140 mg        CYP3A4                  Quinoneimine,\             Li et al., 2009 \[[@B15-ijms-19-02367]\].
                                                                     Imine methide              

  Gefitinib               250 mg             CYP3A4\                 Quinoneimine               Li et al., 2009 \[[@B16-ijms-19-02367]\].
                                             CYP1A1                                             

  Erlotinib               150 mg             CYP3A4, CYP1A1\         Quinoneimine,\             Li et al., 2010 \[[@B17-ijms-19-02367]\].\
                                             CYP3A4/5                Ketene intermediate        Zhao et al., 2018 \[[@B31-ijms-19-02367]\].

  Lapatinib               1250--1500 mg      CYP3A4/5                Quinoneimine,\             Teng et al., 2010 \[[@B18-ijms-19-02367]\].\
                                                                     Nitroso intermediate       Takakusa et al., 2011 \[[@B19-ijms-19-02367]\].

  Imatinib                300--800 mg        CYP3A4                  Imine, Imine methide       Li et al., 2014 \[[@B20-ijms-19-02367]\].

  Axitinib                5 mg BID           CYP3A4                  Possible epoxide           Wang et al., 2014 \[[@B21-ijms-19-02367]\].

  Ponatinib               45 mg              CYP1A1                  Possible epoxide           Lin et al., 2017 \[[@B22-ijms-19-02367]\].

  Sunitinib               37.5--50 mg        CYP1A2, CYP3A4          Quinoneimine               Amaya et al., 2018 \[[@B23-ijms-19-02367]\].

  Saracatinib (azd0530)                      CYP3A4                  *ortho*-Quinone            Chen et al., 2016 \[[@B33-ijms-19-02367]\].

  Masitinib                                                          Imine, Imine carbonyl      Amer et al., 2017 \[[@B34-ijms-19-02367]\].
  -----------------------------------------------------------------------------------------------------------------------------------------------

*^a^* Dosage information was obtained from drug prescribing information.
